Stock 601607 SHANGHAI PHARMACEUTICALS HOLDING CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shanghai Pharmaceuticals Holding Co., Ltd

Equities

601607

CNE000000C82

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
17.85 CNY +0.22% Intraday chart for Shanghai Pharmaceuticals Holding Co., Ltd +0.34% +6.69%
Apr. 26 Shanghai Pharmaceuticals Holding Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 01 Shanghai Pharma's Profit Plunges 33% in 2023 Despite 12% Revenue Growth; Shanghai Shares Rise 4% MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 47,781 47,493 49,277 60,072 56,107 59,329 - -
Enterprise Value (EV) 1 63,090 55,488 57,141 69,931 69,900 77,745 78,742 69,421
P/E ratio 12.8 x 12.2 x 11.1 x 11.1 x 16.4 x 12.4 x 10.9 x 9.5 x
Yield 2.4% 2.5% 2.11% 3.42% 2.45% 3.35% 3.77% 4.11%
Capitalization / Revenue 0.26 x 0.25 x 0.23 x 0.26 x 0.22 x 0.21 x 0.19 x 0.17 x
EV / Revenue 0.34 x 0.29 x 0.26 x 0.3 x 0.27 x 0.27 x 0.25 x 0.2 x
EV / EBITDA 8.22 x 5.85 x 5.53 x 6.24 x 7.47 x 6.43 x 6.03 x 4.84 x
EV / FCF 19.3 x 13.2 x 60.6 x 31.5 x 28.6 x 40.4 x 121 x 20.2 x
FCF Yield 5.18% 7.6% 1.65% 3.17% 3.49% 2.48% 0.83% 4.96%
Price to Book 1.25 x 1.2 x 1.14 x 0.98 x 0.9 x 0.92 x 0.86 x 0.82 x
Nbr of stocks (in thousands) 2,842,089 2,842,089 2,842,089 3,696,414 3,703,301 3,703,301 - -
Reference price 2 18.37 19.20 19.87 17.83 16.73 17.85 17.85 17.85
Announcement Date 3/27/20 3/26/21 3/29/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 186,566 191,909 215,824 231,981 260,295 288,750 317,121 348,524
EBITDA 1 7,672 9,483 10,324 11,216 9,360 12,096 13,063 14,345
EBIT 1 6,214 7,184 8,205 9,015 7,667 10,546 11,514 12,844
Operating Margin 3.33% 3.74% 3.8% 3.89% 2.95% 3.65% 3.63% 3.69%
Earnings before Tax (EBT) 1 6,262 7,175 8,144 8,808 7,054 9,269 10,056 11,287
Net income 1 4,081 4,496 5,093 5,617 3,768 5,182 5,852 6,466
Net margin 2.19% 2.34% 2.36% 2.42% 1.45% 1.79% 1.85% 1.86%
EPS 2 1.440 1.580 1.790 1.610 1.020 1.437 1.642 1.879
Free Cash Flow 1 3,269 4,219 942.6 2,219 2,440 1,925 650.1 3,442
FCF margin 1.75% 2.2% 0.44% 0.96% 0.94% 0.67% 0.2% 0.99%
FCF Conversion (EBITDA) 42.61% 44.49% 9.13% 19.78% 26.07% 15.92% 4.98% 23.99%
FCF Conversion (Net income) 80.11% 93.83% 18.51% 39.5% 64.76% 37.16% 11.11% 53.23%
Dividend per Share 2 0.4400 0.4800 0.4200 0.6100 0.4100 0.5977 0.6735 0.7329
Announcement Date 3/27/20 3/26/21 3/29/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 55,735 54,852 - 54,809 62,904 57,369 66,226 66,366 64,916 62,787 70,153 72,069 75,528 74,375 63,666
EBITDA 1 - - - - - - - - - - 10,925 8,320 -7,752 -534.3 2,498
EBIT 1 1,571 1,404 - 3,804 1,822 1,393 2,666 1,893 1,998 1,489 10,500 7,894 -8,177 -960.1 2,046
Operating Margin 2.82% 2.56% - 6.94% 2.9% 2.43% 4.02% 2.85% 3.08% 2.37% 15.84% 10.95% -10.83% -1.29% 3.21%
Earnings before Tax (EBT) 1 - - - - - - - - - - 10,369 7,745 -8,373 -1,136 1,891
Net income 1 - - - - - - - - - - 9,663 6,933 -9,432 -2,089 1,115
Net margin - - - - - - - - - - 14.57% 9.62% -12.49% -2.81% 1.75%
EPS 2 0.3200 0.2100 0.4400 0.6900 0.3000 0.1600 0.4100 0.3000 0.3200 -0.0100 1.520 1.131 -1.133 -0.0820 0.3656
Dividend per Share 2 - - - - - - - - - - - 0.5522 - - -
Announcement Date 10/29/21 3/29/22 4/28/22 8/29/22 10/27/22 3/30/23 4/26/23 8/29/23 10/27/23 3/28/24 4/26/24 - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 15,309 528 7,864 9,858 13,792 13,267 19,413 10,092
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.995 x 0.0568 x 0.7617 x 0.879 x 1.474 x 1.097 x 1.486 x 0.7035 x
Free Cash Flow 1 3,269 3,835 943 2,219 2,440 1,925 650 3,442
ROE (net income / shareholders' equity) 10.1% 10.3% 10.8% 9.11% 5.56% 7.5% 8.41% 8.49%
ROA (Net income/ Total Assets) 3.09% 3.14% 3.26% 3.11% 1.84% 2.81% 2.87% 2.95%
Assets 1 131,943 143,105 156,308 180,784 205,005 184,485 203,674 218,818
Book Value Per Share 2 14.70 16.00 17.40 18.10 18.50 19.50 20.70 21.80
Cash Flow per Share 2 2.120 2.410 1.780 1.280 1.410 1.170 2.930 2.220
Capex 1 2,753 3,010 4,119 2,525 2,791 3,237 3,208 3,113
Capex / Sales 1.48% 1.57% 1.91% 1.09% 1.07% 1.12% 1.01% 0.89%
Announcement Date 3/27/20 3/26/21 3/29/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Shanghai Pharmaceuticals Holding Co., Ltd

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
17.85 CNY
Average target price
20.78 CNY
Spread / Average Target
+16.42%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+6.69% 8.19B
MCKESSON CORPORATION Stock McKesson Corporation
+17.35% 71.39B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+5.38% 8.59B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-20.96% 7.91B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+0.49% 4.54B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+17.12% 4.31B
EBOS GROUP LIMITED Stock EBOS Group Limited
-3.38% 3.93B
GALENICA AG Stock Galenica AG
-2.61% 3.86B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+22.08% 3.64B
MEDIPAL HOLDINGS CORPORATION Stock MediPal Holdings Corporation
+7.96% 3.29B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. 601607 Stock
  4. Financials Shanghai Pharmaceuticals Holding Co., Ltd